Grand Pharmaceutical Group (HKSE:00512) 3-Year EBITDA Growth Rate : 5.30% (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Grand Pharmaceutical Group 3-Year EBITDA Growth Rate?

Grand Pharmaceutical Group's EBITDA per Share for the six months ended in Dec. 2023 was HK$0.32.

During the past 12 months, Grand Pharmaceutical Group's average EBITDA Per Share Growth Rate was -2.60% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 5.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 12.80% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 18.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Grand Pharmaceutical Group was 164.00% per year. The lowest was 5.30% per year. And the median was 23.70% per year.

Competitive Comparison of Grand Pharmaceutical Group's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grand Pharmaceutical Group's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Grand Pharmaceutical Group's 3-Year EBITDA Growth Rate falls into.

Grand Pharmaceutical Group 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Grand Pharmaceutical Group (HKSE:00512) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Grand Pharmaceutical Group 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Grand Pharmaceutical Group's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Grand Pharmaceutical Group (HKSE:00512) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grand Pharmaceutical Group Ltd (HKSE:00512) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

MX6A:Germany

Address

99 Queen's Road, Units 3302, 33rd Floor, The Center, Central, Hong Kong, HKG

Website

http://www.chinagrandpharm.com

Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a drug manufacturer. The company through its subsidiaries manufactures and sells pharmaceutical preparations and medical devices, biotechnology products, nutrition products, specialized pharmaceutical raw materials, and other products. Geographically, it derives a majority of revenue from China and also has a presence in America; Europe; Asia other than the PRC and others.

Grand Pharmaceutical Group (HKSE:00512) Headlines

No Headlines